Professor Jacky
Smith will present on the correlation between the change in
objective cough count and improvement in patient-reported outcomes
with nalbuphine ER in IPF patients
NEW
HAVEN, Conn., Sept. 4,
2024 /PRNewswire/ -- Trevi Therapeutics, Inc. (Nasdaq:
TRVI), a clinical-stage biopharmaceutical company developing the
investigational therapy Haduvio™ (oral nalbuphine ER) for the
treatment of chronic cough in idiopathic pulmonary fibrosis (IPF)
and refractory chronic cough (RCC), today announced that data from
the Phase 2a CANAL trial will be presented at the European
Respiratory Society (ERS) Congress 2024 being held in Vienna, Austria from September 7-11. The presentation will take place
on September 8th.
European Respiratory Society (ERS) Congress
2024
September 7-11, 2024,
Vienna, Austria
Poster Session: Research studies in chronic cough
Session Date & Time: September
8, 8:00 a.m. – 9:30 a.m. CET
Location: PS-10
Abstract Accepted for Oral Presentation: Change in objective
cough count correlates with improvement in patient-reported
outcomes of cough in patients with idiopathic pulmonary
fibrosis
Presenter: Jacky Smith, MB, ChB, FRCP, PhD, Professor of
Respiratory Medicine at the University of Manchester, and an Honorary Consultant at
Manchester University NHS Foundation Trust. Director of the NIHR
Manchester Clinical Research Facility, Respiratory Theme Lead in
the NIHR Manchester Biomedical Research Centre and a NIHR Senior
Investigator.
Registration details: Registration - ERS Congress -
official website (ersnet.org)
"I am delighted to discuss the correlation between the objective
cough monitor and improvements in patient reported outcomes (PRO)
with nalbuphine ER. PROs act as an important qualitative data point
for clinical trials as they take into consideration the patient
perspective. I am excited to present this data from the Phase 2a
CANAL trial as treatments for chronic cough continue to be a high
unmet need in IPF patients," said Prof. Smith.
About Trevi Therapeutics, Inc.
Trevi Therapeutics,
Inc. is a clinical-stage biopharmaceutical company developing the
investigational therapy Haduvio™ (oral nalbuphine ER) for the
treatment of chronic cough in idiopathic pulmonary fibrosis (IPF)
and refractory chronic cough (RCC). Haduvio is an extended-release
(ER) dual ĸ-opioid receptor agonist and µ-opioid receptor
antagonist that works both centrally in the brain as well as
peripherally in the lungs and has the potential for a synergistic
antitussive effect to treat chronic cough. Parenteral nalbuphine is
not scheduled by the U.S. Drug Enforcement Agency.
The impact of chronic cough is significant and often leads to a
decline in patients' social, physical, and psychological quality of
life. In IPF, chronic cough may lead to worsening disease and may
be associated with a higher risk of progression, death, or need for
lung transplant. There are no approved therapies for the treatment
of chronic cough in IPF and current treatment options provide
minimal benefit to patients. Chronic cough affects up to 10% of the
adult population, and Haduvio's expansion into RCC has the
potential to reach patients suffering from moderate to severe
refractory chronic cough. There are also no approved therapies for
RCC in the U.S.
Trevi intends to propose Haduvio as the trade name for oral
nalbuphine ER. Its safety and efficacy have not been evaluated by
any regulatory authority.
For more information, visit www.TreviTherapeutics.com and
follow Trevi on X (formerly Twitter) and LinkedIn.
Investor Contact
Katie
McManus
Trevi Therapeutics, Inc.
203-304-2499
k.mcmanus@trevitherapeutics.com
Media Contact
Rosalia
Scampoli
914-815-1465
rscampoli@marketcompr.com
View original content to download
multimedia:https://www.prnewswire.com/news-releases/trevi-therapeutics-announces-oral-presentation-on-data-from-ph2a-canal-trial-at-the-european-respiratory-society-congress-2024-302238223.html
SOURCE Trevi Therapeutics, Inc.